Biodexa Pharmaceticals
Yahoo Finance • 16 days ago
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading
European equities traded in the US as American depositary receipts were tracking lower late Monday m PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 22 days ago
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 27 days ago
Biodexa Announces Pricing of $10 Million Public Offering
December 18, 2025 Biodexa Announces Pricing of $10 Million Public Offering Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products... Full story
Yahoo Finance • last month
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European equities traded in the US as American depositary receipts were on the rise late Thursday mo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • last month
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company deve... Full story
Yahoo Finance • 2 months ago
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
November 3, 2025 Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion Biodexa Pharmaceuticals PLC (“Bi... Full story
Yahoo Finance • 3 months ago
Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025
October 6, 2025 Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical sta... Full story
Yahoo Finance • 4 months ago
Biodexa Pharmaceuticals files $100M shelf for flexible securities offerings
* Biodexa Pharmaceuticals (NASDAQ:BDRX [https://seekingalpha.com/symbol/BDRX]) has filed a $100M shelf registration for future offerings of various securities. * Securities may include ordinary shares ADS representing ordinary shares d... Full story
Yahoo Finance • 4 months ago
Biodexa Pharmaceuticals GAAP EPS of £0.00
* Biodexa Pharmaceuticals press release [https://seekingalpha.com/pr/20230561-interim-results-for-the-six-months-ended-june-30-2025] (NASDAQ:BDRX [https://seekingalpha.com/symbol/BDRX]): 1H GAAP EPS of £0.00. MORE ON BIODEXA PHARMACEUTIC... Full story
Yahoo Finance • 4 months ago
Interim results for the six months ended June 30, 2025
September 12, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipe... Full story
Yahoo Finance • 5 months ago
Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
August 18, 2025 Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Opportunity to be First Mover in $7.3Bn Addressable Market Biodexa Pharmaceuticals PLC (“Biodexa”... Full story
- NVDA
Mentioned:
Yahoo Finance • 5 months ago
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.74%
Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Healthcare, Consumer Goods and Financials sectors led shares lower. At the close in NYSE, the Dow Jones Industrial Average declined 0.74%, while the S&P... Full story
Yahoo Finance • 5 months ago
ADR Ratio Change Effective
July 31, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Effective ADSs Outstanding Post Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a p... Full story
Yahoo Finance • 6 months ago
Biodexa Pharmaceuticals to implement 1:10 ADR ratio change
NEW YORK - Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), whose stock has declined nearly 76% over the past six months according to InvestingPro data, announced Tuesday it will change the ratio of its American Depositary Receipts (ADRs) effect... Full story
Yahoo Finance • 6 months ago
ADR Ratio Change
July 15, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative pro... Full story
Yahoo Finance • 7 months ago
Results of Annual General Meeting
June 27, 2023 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative product... Full story
Yahoo Finance • 7 months ago
Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharm... Full story
Yahoo Finance • 7 months ago
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)
June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical compan... Full story
Yahoo Finance • 7 months ago
Biodexa Pharmaceuticals changes share nominal value
Cardiff-based Biodexa Pharmaceuticals PLC has announced a significant change in the nominal value of its ordinary shares. The pharmaceutical company, known for its specialization in pharmaceutical preparations, has reduced the nominal valu... Full story
